文献速递肝病消化道肿瘤与早癌

早期肝细胞癌成功治疗后使用直接抗病毒药物可改善丙型肝炎肝硬化患者生存

Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
PubMed 文献 · J Hepatol · 2019-04-06

研究前瞻性纳入163例丙型肝炎肝硬化且首次诊断为早期巴塞罗那临床肝癌0/A期肝细胞癌、经根治性切除或消融后达到完全影像学缓解并后续接受直接抗病毒药物(DAA)治疗的患者,以ITA.LI.CA.队列中328例未接受DAA治疗的患者为对照,经倾向性评分匹配后比较102例DAA组与102例未治疗组。结果显示DAA组总生存显著优于未治疗组(HR 0.39;95%CI 0.17-0.91;p=0.03),肝失代偿发生率显著降低(HR 0.32;95%CI 0.13-0.84;p=0.02),肝细胞癌复发无显著差异(HR 0.70;95%CI 0.44-1.13;p=0.15)。

要点

  • DAA组总生存显著高于未治疗组(HR 0.39;95%CI 0.17-0.91;p=0.03)。
  • DAA组肝失代偿风险显著低于未治疗组(HR 0.32;95%CI 0.13-0.84;p=0.02)。
  • 两组肝细胞癌复发无显著差异(HR 0.70;95%CI 0.44-1.13;p=0.15)。

核心结论

  • 在丙型肝炎相关肝硬化且早期肝细胞癌经成功治疗的患者中,与未接受DAA治疗相比,DAA治疗显著改善总生存。

研究设计与样本

  • 前瞻性纳入163例丙型肝炎相关肝硬化、首次诊断为早期巴塞罗那临床肝癌0/A期肝细胞癌、经根治性切除或消融后达到完全影像学缓解并后续接受DAA治疗的患者。
  • 以ITA.LI.CA.队列中328例未接受DAA治疗的患者为对照,经倾向性评分匹配后比较102例DAA组与102例未治疗组。

主要发现

  • DAA组平均随访21.4个月,7/102例(6.9%)死亡,28/102例(27.5%)肝细胞癌复发,6/102例(5.9%)发生肝失代偿。
  • DAA组总生存显著高于未治疗组(HR 0.39;95%CI 0.17-0.91;p=0.03)。
  • DAA组与未治疗组肝细胞癌复发无显著差异(HR 0.70;95%CI 0.44-1.13;p=0.15)。
  • DAA组肝失代偿发生率显著低于未治疗组(HR 0.32;95%CI 0.13-0.84;p=0.02)。
  • DAA组中持续病毒学应答是总生存(HR 0.02;95%CI 0.00-0.19;p<0.001)、肝细胞癌复发(HR 0.25;95%CI 0.11-0.57;p<0.001)和肝失代偿(HR 0.12;95%CI 0.02-0.38;p=0.02)的显著预测因素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The effectiveness of direct-acting antivirals (DAAs) against hepatitis C virus (HCV), following successful treatment of early hepatocellular carcinoma (HCC), has been studied extensively. However, the benefit in terms of overall survival (OS) remains to be conclusively demonstrated. The aim of this study was to assess the impact of DAAs on OS, HCC recurrence, and hepatic decompensation. METHODS: We prospectively enrolled 163 consecutive patients with HCV-related cirrhosis and a first diagnosis of early Barcelona Clinic Liver Cancer stage 0/A HCC, who had achieved a complete radiologic response after curative resection or ablation and were subsequently treated with DAAs. DAA-untreated patients from the ITA.LI.CA. cohort (n = 328) served as controls. After propensity score matching, outcomes of 102 DAA-treated (DAA group) and 102 DAA-untreated patients (No DAA group) were compared. RESULTS: In the DAA group, 7/102 patients (6.9%) died, HCC recurred in 28/102 patients (27.5%) and hepatic decompensation occurred in 6/102 patients (5.9%), after a mean follow-up of 21.4 months. OS was significantly higher in the DAA group compared to the No DAA group (hazard ratio [HR] 0.39; 95% CI0.17-0.91; p = 0.03). HCC recurrence was not significantly different between the DAA and No DAA groups (HR0.70; 95% CI0.44-1.13; p = 0.15). A significant reduction in the rate of hepatic decompensation was observed in the DAA group compared with the No DAA group (HR0.32; 95% CI0.13-0.84; p = 0.02). In the DAA group, sustained virologic response was a significant predictor of OS (HR 0.02; 95% CI 0.00-0.19; p <0.001), HCC recurrence (HR 0.25; 95% CI 0.11-0.57; p <0.001) and hepatic decompensation (HR 0.12; 95% CI 0.02-0.38; p = 0.02). CONCLUSIONS: In patients with HCV-related cirrhosis who had been successfully treated for early HCC, DAAs significantly improved OS compared with No DAA treatment. LAY SUMMARY: We aimed to determine whether direct-acting antivirals (DAAs) significantly improve overall survival in patients with hepatitis C virus-related compensated cirrhosis and a first diagnosis of hepatocellular carcinoma (HCC) which has been successfully treated with curative resection or ablation. Using propensity-score matched patients, we found that DAAs improved overall survival and reduced the risk of hepatic decompensation. However, the risk of HCC recurrence was not significantly reduced.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Cabibbo G, Celsa C, Calvaruso V, et al. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. J Hepatol. 2019. PMID: 30959157. doi:10.1016/j.jhep.2019.03.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。